Targets › GYRA
5 programs from 5 companies in 7 trials: 2 Phase 3, 2 Phase 4, 2 Phase 2, 1 Phase 1; Infectious disease, Respiratory, Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on GYRA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Assiut University | Levofloxacin DNA gyrase inhibitor; Topoisomerase IV inhibitor | GYRA, GYRB | Phase 4 | Bronchiectasis With Acute Exacerbation | Feb 2027 |
| Mahidol University | Levofloxacin DNA gyrase inhibitor; Topoisomerase IV inhibitor | GYRA, GYRB | Phase 4 | Bacteremia | Dec 2027 |
| Huashan Hospital | Levofloxacin DNA gyrase inhibitor; Topoisomerase IV inhibitor | GYRA, TOPOISOMERASE | Phase 3 | Multidrug Resistant Tuberculosis; Drug-resistant Tuberculosis | Dec 2026 |
| Copenhagen Respiratory Research | Levofloxacin DNA gyrase inhibitor; Topoisomerase IV inhibitor | GYRA, GYRB | Phase 2 | Community-acquired Pneumonia; Community Acquired Pneumonia (CAP) | Sep 2028 |
| National University Hospital, Singapore | Ciprofloxacin Bacterial DNA gyrase inhibitor; Topoisomerase IV inhibitor | GYRA, GYRB | Phase 1 | Metastatic Pancreatic Ductal Adenocarcinoma | Feb 2027 |
Multidrug Resistant Tuberculosis (1) Drug-resistant Tuberculosis (1) Bronchiectasis With Acute Exacerbation (1) Community-acquired Pneumonia (1) Community Acquired Pneumonia (CAP) (1) Metastatic Pancreatic Ductal Adenocarcinoma (1) Bacteremia (1)
small molecule (4)
Huashan Hospital (1) Assiut University (1) Copenhagen Respiratory Research (1) National University Hospital, Singapore (1) Mahidol University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.